Interestingly, intravenous administration of the NOS inhibitor NΩ-nitro-L-arginine (L-NNA) reduced the tumor blood supply in patients with non-small-cell lung cancer providing the early clinical evidence that inhibition of NOS has antivascular activity in cancer [75]. This evidence concerns the gene NOS2 and non-small cell lung carcinoma.